Turning Point Brands experienced notable downward pressure and share price corrections following regulatory headwinds and reports of heightened scrutiny from the Food and Drug Administration regarding modern nicotine pouches. Investor sentiment softened as market participants worried that stricter regulatory approval pathways, potential marketing restrictions, and health safety reviews could decelerate growth in its fast-expanding alternative tobacco and oral nicotine product segments.